As is known to us all, in the process of gas phase analysis, column is the “heart” of gas chromatograph, and it plays a crucial role in the qualitative and quantitative analysis of components. Recently, followers often consult about the aging of GC column. Today, we would like to share that with you.

Aging of GC column, in short, refers to the process of restoring column efficiency by baking the column at high temperature and taking the unstable stationary phase, possible impurities and pollutants out of the column by carrier gas.

What are the conditions that require aging treatment of the column?

1. Newly purchased column: For new column, prior to its initial use, the aging treatment can remove the stationary liquid that bonded unstably in the column or residual solvent in the packed column to ensure the stability of the properties of the new column.

2. For columns that have been left unused for a long time and need to be started again, the aging of the column can remove pollutants, oxygen and water caused by column being placed for a long time. And restore the properties of the column.

3. Columns that have been used for a long time or that have been through complex matrices and mass sample analysis: in this case, high boiling point impurities and pollutants remaining in the column can be mainly removed by aging; On the other hand, long-term use of column under high temperature will cause the loss of stationary liquid, exposing part of the active site. Through aging treatment, using the characteristics of thermal expansion and cold shrinkage of stationary phase, the active site on the inner wall of the column can be covered again. And restore the properties of the column.

How to operate, and what details do we need to pay attention to during the aging process?

1. Selection of aging temperature

In general, the aging temperature can be controlled between the maximum analytical temperature of the method and the upper limit of the constant temperature of the column.


The aging temperature can also be set to 20-30℃ lower than the upper limit of the column constant temperature; Or 20-30℃ higher than the maximum analysis temperature of the method.

It is important to note that each GC column has a temperature limit to which it can tolerate, and it is necessary to read the column box or instructions carefully before aging. In the aging process, once the column temperature limit is exceeded, it will lead to the loss of stationary phase and shorten the lifetime. Therefore, aging temperature can be lower as far as possible under the premise of ensuring the removal of impurities and pollutants.

2. Aging time

The specific aging process is generally set as program heating (slowly heating up to the set aging temperature), such as: the initial temperature is 35℃, 2-5℃/min, heating up to the aging temperature, and keeping 0.5-2h. The specific aging time can be determined according to the effect of impurity removal.

3. Prevent oxygen into the column

Because at high temperatures, with the presence of oxygen, the stationary liquid is easily oxidized, the stable silane bond will break, causing serious column loss and column efficiency declination.

Therefore, in order to avoid oxygen entering the column, the following points should be noted:

● Connect the gas inlet of the column to the injection port of the instrument. Place the end of the column in alcohol and take carrier gas to observe whether there are continuous bubbles. If not, check the column for mid-section fracture, installation, and leakage of the system.

● Set the carrier gas flow rate to the normal working value, the injection port, column oven and detector (if connected to the detector) to 35℃ or turned off the instrument temperature control system. The carrier gas is available for 15-30 minutes at room temperature to replace the oxygen that may exist in the instrument system and the column.

● Ensure that the other joints of the instrument are properly installed and pass leaking test.

4. Avoid pollution

In general, in order to avoid contamination of the detector, it is not recommended to connect the detector during the aging process. The normal operation is to use a solid pressure ring to plug the lower end of the detector and close the temperature. If the detector is connected, for the FID detector, there is no need to ignite, and air and hydrogen need not be turned on; If it is an ECD detector, tailing blowing should be set to avoid excessive heat and temperature which transfer to the ECD, so as to ensure the safety of the radioactive source inside the detector. In addition, it is prohibited to use hydrogen to age the column, that is to avoid hydrogen leakage and accumulation in the column temperature chamber, which will cause explosion.

5. Relevant maintenance shall be carried out before aging

For columns that have been used for a long time or that have through analysis of complex matrices and multiple samples, aging is to remove some of the residual contaminants. These contaminants tend to be compounds with higher boiling points which accumulate at the head of the column, such as proteins, pigments, gels, etc. in the sample. In order to avoid the pollutants to continue to transfer to the column while they can not be completely removed from the column inside the column, before aging column should be cut, appropriately cut off part of the column. In addition, it is necessary to maintain the injector liner, quartz cotton and the injector spacer to avoid secondary contamination of the column in the aging process. In conclusion, aging of column is meaningful after removing the source of pollution.

Aging Of Column

Posted by kaushik zala
Tag :

Peak Fronting Tailing peaks are almost ubiquitous in liquid chromatography (LC) separations. Over the past 20 years of "LC Troubleshooting," at least a dozen instalments of this feature have dealt with tailing peaks. In the days of lower-purity silica, peak tailing was often the result of strong acid-base interactions between basic sample functional groups, such as amines and acidic silanol groups on the silica surface. One popular way to combat such tailing was to add triethylamine to the mobile phase to saturate the stationary phase's acidic sites. With the widespread use of high-purity silica as the backbone of most of today's reversed-phase columns, tailing problems have been reduced to the extent that amine mobile phase additives are seldom used. Today, silanol tailing remains, but is much less of a problem. Another common cause of peak tailing, column overload, was discussed in last month's "LC Troubleshooting" instalment.1 Peak fronting is much more rare than peak tailing. There is some speculation that complaints are low because peak fronting merely makes a badly tailing peak look more symmetric, but this is a viewpoint for cynics. In our laboratory, we rarely see fronting peaks, and this is likely the problem in most scientists' experience. One classic example of fronting in ion-pair chromatography showed that peak fronting could be eliminated with a change in the column temperature.2 A previous "LC Troubleshooting" column discussed another case in which peak fronting might have been attributable to a void in the column or the mobile phase problems, but the cause of the problem was not definitive.3


A satisfactory chemical model for peak fronting in reversed-phase LC with most samples is difficult to postulate. However, a problem with the physical structure of the column is more reasonable. An asymmetric void at the head of the column, channelling within the column, or a less dense bed structure along the walls off the column than in the middle, each creates a model that allows one to visualize the fronting process. If a portion of the sample molecules travel through this less dense part of the column, they will travel more quickly, distorting the peak. If the bulk of the peak is retained in the normal fashion, a fronting peak will occur.
We recently observed a case of severe peak fronting that appears to fit the hypothesis of a column void or distortion in the column bed. The LC–tandem mass spectrometry (LC–MS–MS) method uses a 100 mm × 2.1 mm C18 column packed with 5 μm diameter particles designed to work well with 100% aqueous phases. Mobile phase A was 10 mM ammonium carbonate (pH 9.0), and mobile phase B was methanol. An isocratic mobile phase of 5% B was run for 5 min at a flow-rate of 0.5 mL/min, followed by an 80% methanol flush. Normally, the method produces chromatograms with symmetric peaks. After approximately 500 injections of extracted plasma samples, the chromatograms had deteriorated to the degree. Column reversal was ineffective and normal pressures were observed, suggesting that frit blockage was not the problem source. The column was replaced and the chromatogram was similar to initial. We have seen this failure pattern for several columns, indicating that a column lifetime of approximately 500 injections is typical for this method.


Column Life Expectancy Replacement of the column after 500 injections of the sample above might bring some gasps of horror from some readers. A question we hear frequently relates to how long a column should last. We have methods in our laboratory for which column lifetime of 2000 injections are common. Conversely, we've had users tell us of methods in which column failure is observed after 50 or fewer injections — and they are not upset.
Before going into techniques to extend column life, we should consider the cost of the column in the big scheme of things. We work in a contract research organization (CRO), so we make our living from running other people's samples. In the CRO world, LC sample analysis costs generally are $50/sample and up. For our earlier example, the column costs about $500; at 500 samples/column, this translates to $1/sample or 2% of the cost. If we could double the life of the column, we would only reduce the cost to 1%, hardly worth the trouble. However, with a $500 column, many people seem to treat the column as a capital item instead of a consumable. Contrast this with a method that uses solid-phase extraction (SPE) for sample clean-up. SPE cartridges or 96-well plates cost at least $2/sample. This is twice the cost of the analytical column, yet we think nothing of throwing the SPE cartridges away after a single use — they are sold as consumable items. Rather than trying to improve column life, a better investment for cost reduction is to figure out ways to reduce labour costs or improve throughput of expensive LC–MS–MS detectors by the use of techniques such as parallel chromatography.4

Extending Column Life Although this discussion should convince us that we do not want to spend too much time trying to extend column life, there are some simple techniques that will extend the useful life of a column. The most common mode of failure of columns today is excessive pressure resulting from build-up of particulate matter at the head of the column. Make sure that your samples are free of particulates. Filtration of each sample or centrifugation of samples to eliminate particles will go a long way towards this goal. Another inexpensive, but very effective tool is a 0.5 μm porosity in-line filter mounted just downstream from the autosampler. This will catch the particles that make it past your filtration or centrifugation efforts so that they do not block the column inlet frit. When the system pressure rises to an unacceptable level, simply replace the frit in the filter and you should be back in business. Many workers find that guard columns are beneficial to improving column life. These small columns upstream from the analytical column catch both particulate matter and strongly retained materials that might foul the column packing on the analytical column. If you use guard columns, be sure to discard them before the contaminants break through onto the main column. Also, when flushing the system with strong solvent, be sure to flush the guard column to waste, not onto the analytical column, or you might defeat the purpose of the guard column.
Sample clean-up is another technique to extend column usefulness. You need to remember that there is an economic balance in sample clean-up versus column costs. Does it make sense to spend $10/sample for clean-up to reduce the per-sample cost of the column's contribution from $2/sample to $1/sample? In our opinion, one major goal of sample clean-up should be to improve method ruggedness so that you are assured of collecting meaningful data from your samples. Some workers perform the absolute minimum of clean-up, expect their columns to do the clean-up work, and are satisfied if the column lasts for 100 samples. In other instances, extensive sample clean-up can lower the background noise and allow a 10-fold lower limit of quantification; longer column life is only a peripheral benefit. You have to work out the economics on a case-by-case basis.

Column Conditioning You might have noticed that some LC methods take a while before they "settle down" and give consistent results. For example, it may take five or six injections before the retention time, peak height or peak area stabilizes to a satisfactory level of variability. What is going on? Many workers think of a reversed-phase separation as simple partition-like separation between the mobile phase and a homogeneous stationary phase surface. Unfortunately, this is not the situation. The closer you look, the less homogeneous the stationary phase appears. In some instances, there are slow and fast equilibria going on at the same time. Sometimes the analyte molecules are retained by more than one mechanism. Loading sample onto the column might allow the slow-equilibrium mechanism to saturate so consistent results are seen. In other instances, it might be proteins, polymers or other analytically unimportant matrix materials that must be loaded onto the column before the method behaves well. Injection of several mock samples will usually suffice. We have several methods that include five to ten conditioning injections before injecting the standard curve. This is alright if the runtime is short, but if the method is a conventional LC–UV method, the runtime may be 20–30 min, so extensive conditioning might be unacceptable from a sample-throughput standpoint. Because the conditioning process is often related to the mass of sample (or matrix) loaded on the column, one might be able to shorten the conditioning cycle by making the conditioning injections one after the other without waiting for elution to occur. For example, if the method has a 20 min runtime, just start the method, and then make five injections at 30 s intervals rather than waiting for 20 min for each one. An alternative is to make a single large-mass injection. Try one or more of these techniques and see if it will help your method settle down quickly for normal operation.

References 1. John W. Dolan, LCGC Eur.,18(6), 318–322 (2005).
2. P.A. Asmus, J.B. Landis and C.L. Vila, J. Chromatogr. 264, 241 (1983).
3. C. Hawkins and J.W. Dolan, LCGC Eur., 17(1), 32–40 (2004).
4. M.D. Nelson and J.W. Dolan, LCGC Eur., 17(5), 272–277 (2004).


yours chormatographically,

kaushik zala




1.      Instrument performance
ICP-OES quantitation is based on measurement of excited atoms and ions at the wavelength characteristics for the specific elements being measured. ICP-MS, however, measures an atom’s mass by mass spectrometry (MS). Due to the difference in metal element detection, the lower detection limit for ICP-MS can extend to parts per trillion (ppt), where the lower limit for ICP-OES is parts per billion (ppb). Obviously, if the elements for detection have regulatory limits that are below or near the lower detection limit of ICP-OES, ICP-MS is the instrument of choice.
2.      Characteristics of the environmental sample
ICP-OES is mainly used for samples with high total dissolved solids (TDS) or suspended solids and is, therefore, more robust for analyzing ground water, wastewater, soil, and solid waste. It can be used for drinking water analysis as well. But in general, ICP-OES is used to measure contaminants for environmental safety assessment and elements with a higher regulatory limit. ICP-MS, on the other hand, is especially useful for analyzing samples with low regulatory limits. In addition, ICP-OES has much higher tolerance for TDS (up to 30%). ICP-MS has much lower tolerance for TDS (about 0.2%) although there are ways to increase the tolerance. Although both ICP-OES and ICP-MS can be used for high matrix samples, sample dilution is often necessary for use on ICP-MS. In addition, if a sample contains analytes of great difference in concentration, ICP-MS has wider dynamic linear range so the sample may not be diluted to detect these elements at the same time.
3.      Regulatory requirements
In the U.S., the regulatory compliance monitoring for ICP-OES is governed by EPA Methods 200.5 and 200.7. EPA Method 200.7 was approved for use as axial view of ICP-OES and is therefore the EPA method for compliance monitoring by ICP-OES. EPA Method 200.8 governs regulatory compliance using ICP-MS. Both EPA 200.7 and 200.8 can be used for compliance of the Safe Drinking Water Act (SDWA) and the Clean Water Act (CWA).
For drinking water regulatory compliance or SDWA compliance, either ICP-OES or ICP-MS alone is not sufficient. Regulatory compliance can be accomplished by the combination of ICP-OES (for minerals) and ICP-MS, or ICP-OES and GFAA (using EPA 200.9), or ICP-MS and GFAA (for minerals). ICP-OES cannot be used to measure arsenic, mercury, and some other toxic metals with very low regulatory limits using EPA Method 200.7. ICP-MS can’t be used to measure the minerals (Na, K, Ca, Mg, and Fe) in drinking water using EPA Method 200.8. It is also important to mention that current EPA Method 200.8 version 5.4 cannot use collision cell technology for drinking water analysis, reducing the power to use ICP-MS to minimize polyatomic interferences.




Comparison of ICP-MS and ICP-OES Advantages and Methods
ICP-MS
Main advantages
ICP-MS is becoming a workhorse for metal analysis in water not only because it offers lower detection limit. The following features also contribute its wide range of environmental applications:
·        Wide dynamic range
·        Efficiently remove polyatomic spectral interferences using collision cell technology
·        Rapid semi-quantitative analysis
·        Isotopic analysis
·        Speciation capability
Regulatory methods
·        EPA 200.8
·        EPA 321.8 (IC-ICP-MS)
·        EPA 6020
·        ISO/DIS 17294-1:2004
·        ISO 17294-2:2016
·        NEN 6427:1999
ICP-OES
Main advantages
ICP-OES is used for all the matrices of environmental samples especially for high-matrix samples. The following features also contribute its wide range of environmental applications:
·        Only analytical grade reagents are sufficient
·        Simpler method development does not need a specialist with highly technical expertise
·        Overall is a cheaper option if the elements do not need lower detection limit that ICP-MS delivers
Regulatory methods
·        EPA 200.5
·        EPA 200.7
·        EPA 6010
·        ISO 11885:2007
·        ISO/TC 190/SC3/WG1 N0252
·        NPR 6425:1995
·        NEN 6426:1995
·        EN 12506: 2003



Yours Chromatographically
Kaushik Zala




Ref., 
https://www.thermofisher.com/in/en/home/industrial/environmental/environmental-learning-center/contaminant-analysis-information/metal-analysis/comparison-icp-oes-icp-ms-trace-element-analysis.html



Separation science is always looking for new and effective strategies to accomplish the tasks of modern analytics. Especially for polar compounds reversed phase HPLC – the most common analytical method – is often limited. Here, hydrophilic stationary phases provide an additional tool for the separation of polar analytes in HPLC.
The expression HILIC (Hydrophilic Interaction Chromatography) was firstly published by Andrew Alpert in 1990 – since then it took quite some efforts to develop robust and reproducible hydrophilic HPLC phases for HILIC chromatography [A. Alpert, J. Chromatography 499 (1990), 177–196].

HILIC combines the characteristics of the 3 major methods in liquid chromatography – reversed phase (RPC), normal phase (NPC) and ion chromatography (IC):
Stationary phases (adsorbents) are mostly polar modifications of silica or polymers (SiOH, Amino, Diol, (zwitter) ions, …) – like in NPC.
Mobile phases (eluents) are mixtures of aqueous buffer systems and organic modifiers like acetonitrile or methanol – like in RPC.
Fields of application include quite polar compounds as well as organic and inorganic ions – like in IC.



HILIC is NP chromatography of polar and ionic compounds under RP conditions.”





Retention characteristics
Commonly HILIC is described as partition chromatography or liquid/liquid extraction system between the mobile and stationary phase. Versus a water-poor layer of mobile phase a water-rich layer on the surface of the polar stationary phase is formed. Thus, a distribution of the analytes between these two layers will occur.

Furthermore HILIC includes weak electrostatic mechanisms as well as hydrogen donor interactions between neutral polar molecules under high organic elution conditions. This distinguishes HILIC from ion exchange chromatography - main principle for HILIC separation is based on compound’s polarity and degree of solvation.

More polar compounds will have stronger interaction with the stationary aqueous layer than less polar compounds – resulting in a stronger retention.

Nonpolar compounds exhibit faster elution profiles due to minor hydrophobic interactions. Thus, as shown for the separation of uracil and naphthalene the elution order is quite often inverse on HILIC columns compared to RP columns.


HILIC seperations

Posted by kaushik zala

Testing to the specification of an ancillary material, intermediate, and/or ingredient and product is critical in establishing the quality of a finished dosage form. The transfer of analytical procedures (TAP), also referred to as method transfer, is the documented process that qualifies a laboratory (the receiving unit) to use an analytical test procedure that originated in another laboratory (the transferring unit), thus ensuring that the receiving unit has the procedural knowledge and ability to perform the transferred analytical procedure as intended. The purpose of this general information chapter is to summarize the types of transfers that may occur, including the possibility of waiver of any transfer, and to outline the potential components of a transfer protocol. The chapter does not provide statistical methods and does not encompass the transfer of microbiological or biological procedures.

TYPES OF TRANSFERS OF ANALYTICAL PROCEDURES

TAP can be performed and demonstrated by several approaches. The most common is comparative testing performed on homogeneous lots of the target material from standard production batches or samples intentionally prepared for the test (e.g., by spiking relevant accurate amounts of known impurities into samples). Other approaches include covalidation between laboratories, the complete or partial validation of the analytical procedures by the receiving unit, and the transfer waiver, which is an appropriately justified omission of the transfer process. The tests that will be transferred, the extent of the transfer activities, and the implementation strategy should be based on a risk analysis that considers the previous experience and knowledge of the receiving unit, the complexity and specifications of the product, and the procedure.

Comparative Testing

Comparative testing requires the analysis of a predetermined number of samples of the same lot by both the sending and the receiving units. Other approaches may be valid, e.g., if the receiving unit meets a predetermined acceptance criterion for the recovery of an impurity in a spiked product. Such analysis is based on a preapproved transfer protocol that stipulates the details of the procedure, the samples that will be used, and the predetermined acceptance criteria, including acceptable variability. Meeting the predetermined acceptance criteria is necessary to assure that the receiving unit is qualified to run the procedure.

Covalidation Between Two or More Laboratories

The laboratory that performs the validation of an analytical procedure is qualified to run the procedure. The transferring unit can involve the receiving unit in an interlaboratory covalidation, including them as a part of the validation team at the transferring unit and thereby obtaining data for the assessment of reproducibility. This assessment is made using a preapproved transfer or validation protocol that provides the details of the procedure, the samples to be used, and the predetermined acceptance criteria. The general chapter Validation of Compendial Procedures (1225) provides useful guidance about which characteristics are appropriate for testing.

Revalidation 

Revalidation or partial revalidation is another acceptable approach for transfer of a validated procedure. Those characteristics described in (1225) ,which are anticipated to be affected by the transfer, should be addressed.

Transfer Waiver

The conventional TAP may be omitted under certain circumstances. In such instances, the receiving unit is considered to be qualified to use the analytical test procedures without comparison and generation of interlaboratory comparative data. The following examples give some scenarios that may justify the waiver of TAP.
• The new product’s composition is comparable to that of an existing product and/or the concentration of active ingredient is similar to that of an existing product and is analyzed by procedures with which the receiving unit already has experience. 
• The analytical procedure being transferred is described in the USP–NF, and is unchanged. Verifiction should apply in this case (see 1226). 
• The analytical procedure transferred is the same as or very similar to a procedure already in use.
The personnel in charge of the development, validation, or routine analysis of the product at the transferring unit are moved to the receiving unit. If eligible for transfer waiver, the receiving receiving unit should document it with appropriate justifications.

ELEMENTS RECOMMENDED FOR THE TRANSFER OF ANAYTICAL PROCEDURES

Several elements, many of which may be interrelated, are recommended for a successful TAP. When appropriate and as a part of pretransfer activities, the transferring unit should provide training to the receiving unit, or the receiving unit should run the procedures and identify any issues that may need to be resolved before the transfer protocol is signed. Training should be documented. The transferring unit, often the development unit, is responsible for providing the analytical procedure, the reference standards, the validation reports, and any necessary documents, as well as for providing the necessary training and assistance to the receiving unit as needed during the transfer. The receiving unit may be a quality control unit, another intracompany facility, or another company such as a contract research organization. The receiving unit provides qualified staff or properly trains the staff before the transfer, ensures that the facilities and instrumentation are properly calibrated and qualified as needed, and verifies that the laboratory systems are in compliance with applicable regulations and in-house general laboratory procedures. Both the transferring and receiving units should compare and discuss data as well as any deviations from the protocol. This discussion addresses any necessary corrections or updates to the final report and the analytical procedure as necessary to reproduce the procedure. A single lot of the article may be used for the transfer, because the aim of the transfer is not related to the manufacturing process but rather to the evaluation of the analytical procedure’s performance at the receiving site.

PREAPPROVED PROTOCOL

A well-designed protocol should be discussed, agreed upon, and documented before the implementation of TAP. The document expresses a consensus between the parties, indicating an intended execution strategy, and should include each party’s requirements and responsibilities. It is recommended that the protocol contain the following topics as appropriate: objective, scope, responsibilities of the transferring and receiving units, materials and instruments that will be used, analytical procedure, experimental design, and acceptance criteria for all tests and/or methods included in the transfer. Based on the validation data and procedural knowledge, the transfer protocol should identify the specific analytical performance characteristics (see 1225 and 1226) that will be evaluated and the analysis that will be used to evaluate acceptable outcomes of the transfer exercise. The transfer acceptance criteria, which are based on method performance and historical data from stability and release results, if available, should include the comparability criteria for results from all study sites. These criteria may be derived using statistical principles based on the difference between mean values and established ranges and should be accompanied by an estimation of the variability (e.g., percent relative standard deviation [%RSD] for each site), particularly for the intermediate precision %RSD of the receiving unit and/or a statistical method for the comparison of the means for assay and content uniformity tests. In instances of impurity testing, where precision may be poorer such as in the case of trace impurities, a simple descriptive approach can be used. Dissolution can be evaluated by a comparison of the dissolution profiles using the similarity factor f2 or by comparison of data at the specified time points. The laboratories should provide appropriate rationale for any analytical performance characteristic not included. The materials, reference standards, samples, instruments, and instrumental parameters that will be used should be described. It is recommended that expired, aged, or spiked samples be carefully chosen and evaluated to identify potential problems related to differences in sample preparation equipment and to evaluate the impact of potential aberrant results on marketed products. The documentation section of the transfer protocol may include report forms to ensure consistent recording of results and to improve consistency between laboratories. This section should contain the additional information that will be included with the results, such as example chromatograms and spectra, along with additional information in case of a deviation. The protocol should also explain how any deviation from the acceptance criteria will be managed. Any changes to the transfer protocol following failure of an acceptance criterion must be approved before collection of additional data.  

THE ANALYTICAL PROCEDURE

The procedure should be written with sufficient detail and explicit instructions, so that a trained analyst can perform it without difficulty. A pretransfer meeting between the transferring and receiving units is helpful to clarify any issues and answer any questions regarding the transfer process. If complete or partial validation data exist, they should be available to the receiving unit, along with any technical details required to perform the test in question. In some cases it may be useful for the individuals who were involved with the initial development or validation to be on site during the transfer. The number of replicates and injection sequences in the case of liquid or gas chromatography should be clearly expressed, and, in the case of dissolution testing, the number of individual dosage units should be stipulated.

TRANSFER REPORT

When the TAP is successfully completed, the receiving unit should prepare a transfer report that describes the results obtained in relation to the acceptance criteria, along with conclusions that confirm that the receiving unit is now qualified to run the procedure. Any deviations should be thoroughly documented and justified. If the acceptance criteria are met, the TAP is successful and the receiving unit is qualified to run the procedure. Otherwise, the procedure cannot be considered transferred until effective remedial steps are adopted in order to meet the acceptance criteria. An investigation may provide guidance about the nature and extent of the remedial steps, which may vary from further training and clarification to more complex approaches, depending on the particular procedure.  

Yours Chromatographically

#KZ

Hydrophilic interaction chromatography (or hydrophilic interaction liquid chromatographyHILIC) is a variant of normal phase liquid chromatography that partly overlaps with other chromatographic applications such as ion chromatography and reversed phase liquid chromatography. HILIC uses hydrophilic stationary phases with reversed-phase type eluents. The name was suggested by Dr. Andrew Alpert in his 1990 paper on the subject.[1] He described the chromatographic mechanism for it as liquid-liquid partition chromatography where analytes elute in order of increasing polarity, a conclusion supported by a review and re-evaluation of published data.[2]

More Coming Soon

Yours Charomatographically

Kaushik Zala

Tag :
Batch: A specific quantity of a drug or other material produced according to a single manufacturing order during the same cycle of manufacture and intended to have uniform character and quality, within specified limits (21 CFR 210.3(b)(2)).

Batch formula (composition): A complete list of the ingredients and their amounts to be used for the manufacture of a representative batch of the drug product. All ingredients should be included in the batch formula whether or not they remain in the finished product (Guideline for Submitting Documentation for the Manufacture of and Controls for Drug Products, FDA, February 1987).

Bioavailability: The rate and extent to which the active drug ingredient or therapeutic moiety is absorbed from a drug product and becomes available at the site of drug action (21 CFR 320.1(a)).

Biobatch: A lot of drug product formulated for purposes of pharmacokinetic evaluation in a bioavailability/bioequivalency study. This lot should be 10% or greater than the proposed commercial production batch or at least 100,000 units, whichever is greater.

Bioequivalent drug products: Pharmaceutical equivalents or pharmaceutical alternatives whose rate and extent of absorption do not show a significant difference when administered at the same molar dose of the therapeutic moiety under similar experimental conditions, either single dose or multiple dose. Some pharmaceutical equivalents or pharmaceutical alternatives may be equivalent in the extent of their absorption but not in their rate of absorption and yet may be considered bioequivalent because such differences in the rate of absorption are intentional and are reflected in the labeling, are not essential to the attainment of effective body drug concentrations on chronic use, or are considered medically insignificant for the particular drug product studied (21 CFR 320.1(e)).

Convolution: Prediction of plasma drug concentrations using a mathematical model based on the convolution integral. For example, the following convolution integral equation may be used to predict the plasma concentration (c(t)) resulting from the absorption rate time course (r ): abs c(t) = I0 c* (t-u) rabs(u) du t The function c represents the concentration time course that would result from the instantaneous * absorption of a unit amount of drug and can be estimated from either i.v. bolus data, oral solution, suspension or rapidly releasing (in vivo) immediate release dosage forms.

Correlation: As used in this guidance, a relationship between in vitro dissolution rate and in vivo input (absorption) rate.

Deconvolution: Estimation of the time course of drug input (usually in vivo absorption or dissolution) using a mathematical model based on the convolution integral. For example, the 22 absorption rate time course (rabs) that resulted in the plasma concentrations (c(t)) may be estimated by solving the following convolution integral equation for r : abs c(t) = I0 c* (t-u) rabs(u) du t The function c represents the concentration time course that would result from the instantaneous * absorption of a unit amount of drug and is typically estimated from either i.v. bolus data, oral solution, suspension or rapidly releasing (in vivo) immediate release dosage forms.

Development: Establishing an in vitro/in vivo correlation.

Drug product: A finished dosage form, e.g., tablet, capsule, or solution, that contains a drug substance, generally, but not necessarily, in association with one or more other ingredients (21 CFR 314.3(b)).

Extended release dosage form: A dosage form that allows a reduction in dosing frequency as compared to that presented by a conventional dosage form, e.g., a solution or an immediate release dosage form

Evaluation: In the context of in vitro/in vivo correlation, a broad term encompassing experimental and statistical techniques used during development and evaluation of a correlation which aid in determining the predictability of the correlation.

Formulation: A listing of the ingredients and composition of the dosage form.

In vitro/in vivo correlation: A predictive mathematical model describing the relationship between an in vitro property of an extended release dosage form (usually the rate or extent of drug dissolution or release) and a relevant in vivo response, e.g., plasma drug concentration or amount of drug absorbed.

In vivo dissolution: The process of dissolution of drug in the gastro-intestinal tract.

In vitro release: Drug dissolution (release) from a dosage form as measured in an in vitro dissolution apparatus

In vivo release: In vivo dissolution of drug from a dosage form as determined by deconvolution of data obtained from pharmacokinetic studies in humans (patients or healthy volunteers).

Level A correlation: A predictive mathematical model for the relationship between the entire in vitro dissolution/release time course and the entire in vivo response time course, e.g., the time course of plasma drug concentration or amount of drug absorbed.

Level B correlation: A predictive mathematical model for the relationship between summary parameters that characterize the in vitro and in vivo time courses, e.g., models that relate the mean in vitro dissolution time to the mean in vivo dissolution time, the mean in vitro dissolution time to the mean residence time in vivo, or the in vitro dissolution rate constant to the absorption rate constant.

Level C correlation: A predictive mathematical model of the relationship between the amount dissolved in vitro at a particular time (or the time required for in vitro dissolution of a fixed percent of the dose, e.g., T50%) and a summary parameter that characterizes the in vivo time course (e.g., Cmax or AUC)

Lot: A batch, or a specific identified portion of a batch, having uniform character and quality within specified limits or, in the case of a drug product produced by continuous process, a specific identified amount produced in a unit of time or quantity in a manner that assures its having uniform character and quality within specified limits (21 CFR 210.3(b)(10)).

Mean absorption time: The mean time required for drug to reach systemic circulation from the time of drug administration. This term commonly refers to the mean time involved in the in vivo release and absorption processes as they occur in the input compartment and is estimated as MAT = MRToral - MRTi.v

Mean in vivo dissolution time: For a solid dosage form: MDT = MRT - MRT . This solid solid solution reflects the mean time for drug to dissolve in vivo.

Mean residence time: The mean time that the drug resides in the body. MRT may also be the mean transit time. MRT = AUMC/AUC.

Narrow therapeutic index drugs: Drugs having, for example, less than a two-fold difference in the minimum toxic concentrations and the minimum effective concentrations (21 CFR 320.33 (c)).

Nonrelease controlling excipient (noncritical compositional variable): An inactive ingredient in the final dosage form that does not significantly affect the release of the active drug substance from the dosage form.

Predictability: Verification of the model's ability to describe in vivo bioavailability results from a test set of in vitro data (external predictability) as well as from the data that was used to develop the correlation (internal predictability)

Percent prediction error: % PE = [(Observed value - Predicted value) / Observed value] x 100

Release controlling excipient (critical compositional variable): An inactive ingredient in the final dosage form that functions primarily to extend the release of the active drug substance from the dosage form.

Release mechanism: The process by which the drug substance is released from the dosage form.

Release rate: Amount of drug released per unit of time as defined by in vitro or in vivo testing.

Statistical moments: Parameters that describe the characteristics of the time courses of plasma concentration (area, mean residence time, and variance of mean residence time) and of urinary excretion rate.
1 Performing Filter Compatibility
 1.2 Determining Solubility and Stability of Drug Substance in Various Media at 37°
 1.3 Choosing a Medium and Volume
1.4 Choosing an Apparatus

1.1 Performing Filter Compatibility 
 Filtration is a key sample-preparation step in achieving accurate test results. The purpose of filtration is to remove undissolved drug and excipients from the withdrawn solution. If not removed from the sample solution, particles of the drug will continue to dissolve and can bias the results. Therefore, filtering the dissolution samples is usually necessary and should be done immediately if the filter is not positioned on the cannula. Filtration also removes insoluble excipients that may otherwise interfere with the analytical procedure during the analytical finish. Selection of the proper filter material is important and should be accomplished, and experimentally justified, early in the development of the dissolution method. Important characteristics to consider when choosing a filter material are type, size, and pore size. The filter that is selected based on evaluation during the early stages of dissolution method development may need to be reconsidered at a later time point. Requalification has to be considered after a change in composition of the drug product or changes in the quality of the ingredients (e.g. particle size of microcrystalline cellulose). Filters used in dissolution testing can be cannula filters, filter disks or frits, filter tips, or syringe filters. The filter material has to be compatible with the media and cannot adsorb the drug. Common pore sizes range from 0.20 to 70 µm, however, filters of other pore sizes can be used as needed. If the drug substance particle size is very small (e.g., micronized or nanoparticles), it can be challenging to find a filter pore size that excludes these small particles. Adsorption of the drug(s) by the filter may occur and needs to be evaluated. Filter materials will interact with dissolution media to affect the recovery of the individual solutes and must be considered on a case-by-case basis. Different filter materials exhibit different drug-binding properties. Drug binding is also dependent on the drug concentration. Therefore the adsorptive interference should be evaluated on sample solutions at different concentrations bracketing the expected concentration range. Where the drug adsorption is saturable, discarding an initial volume of filtrate may allow the collection of a subsequent solution that approaches the original solution concentration. Alternative filter materials that minimize adsorptive interference can usually be found. Prewetting of the filter with the medium may be necessary. In addition, it is important that leachables from the filter do not interfere with the analytical procedure. This can be evaluated by analyzing the filtered dissolution medium and comparing it with the unfiltered medium. The filter size should be based on the volume to be withdrawn and the amount of particles to be separated. Use of the correct filter dimensions will improve throughput and recovery, and also reduce clogging. Use of a large filter for small-volume filtration can lead to loss of sample through hold-up volume, whereas filtration through small filter sizes needs higher pressures and longer times, and the filters can clog quickly. Filters used for USP Apparatus 4 need special attention because they are integrated in the flow-through process. Undissolved particles may deposit on the filters, creating resistance to the flow. In the case of automated systems, selection of the filter with regard to material and pore size can be done in a similar manner to manual filtration. Flow rate through the filter and clogging may be critical for filters used in automated systems. Experimental verification that a filter is appropriate may be accomplished by comparing the responses for filtered and unfiltered standard and sample solutions. This is done by first preparing a suitable standard solution and a sample solution. For example, prepare a typical dissolution sample in a beaker and stir vigorously with a magnetic stirrer to dissolve the drug load completely. For standard solutions, compare the results for filtered solutions (after discarding the appropriate volume) to those for the unfiltered solutions. For sample solutions, compare the results for filtered solutions (after discarding the appropriate volume) to those for centrifuged, unfiltered solutions.

1.2 Determining Solubility and Stability of Drug Substance in Various Media at 37° 

Physical and chemical characteristics of the drug substance need to be determined before selecting the proper dissolution medium. When deciding the composition of the medium for dissolution testing, it is important to evaluate the influence of buffers, pH, and if needed, different surfactants on the solubility and stability of the drug substance. Solubility of the drug substance is usually evaluated by determining the saturation concentration of the drug in different media at 37° using the shake-flask solubility method (equilibrium solubility). Alternative methods for solubility determination may also be used. To level out potential ion effects between the drug and the buffers used in the media, mixtures of hydrochloric acid and sodium hydroxide are used to perform solubility investigations; this is in addition to the typical buffer solutions. In certain cases, it may be necessary to evaluate the solubility of the drug at room temperature (i.e., 20°). The pH of the clear supernatant should be checked to determine whether the pH changes during the solubility test. Typical media for dissolution may include the following (not listed in order of preference): diluted hydrochloric acid; buffers (phosphate or acetate) in the physiologic pH range of 1.2–7.5; simulated gastric or intestinal fluid (with or without enzymes); and water. For some drugs, incompatibility of the drug with certain buffers or salts may influence the choice of buffer. The molarity of the buffers and acids used can influence the solubilizing effect, and this factor may be evaluated. For poorly soluble dugs, aqueous solutions (acidic or buffer solutions) may contain a percentage of a surfactant [e.g., sodium dodecyl sulfate (SDS), polysorbate, or lauryldimethylamine oxide] to enhance the solubility of the drug. The surfactants selected for the solubility investigations should cover all common surfactant types, i.e., anionic, nonionic, and cationic. When a suitable surfactant has been identified, different concentrations of that surfactant should be investigated to identify the lowest concentration needed to achieve sink conditions. Typically, the surfactant concentration is above its critical micellar concentration (CMC). Table 1 shows a list of some of the surfactants used in dissolution media. CMC values are provided with references when available. The list is not comprehensive and is not intended to exclude surfactants that are not listed. Other substances, such as hydroxypropyl β-cyclodextrin, have been used as dissolution media additives to enhance dissolution of poorly soluble compounds. The U.S. Food and Drug Administration maintains a database of dissolution methods, including information on dissolution media that have been used.1 It is important to control the grade and purity of surfactants because use of different grades could affect the solubility of the drug. For example, SDS is available in both a technical grade and a high-purity grade. Obtaining polysorbate 80 from different sources can affect its suitability when performing high-performance liquid chromatography (HPLC) analysis. There may be effects of counter-ions or pH on the solubility or solution stability of the surfactant solutions. For example, a precipitate forms when the potassium salt for the phosphate buffer is used at a concentration of 0.5M in combination with SDS. This can be avoided by using the sodium phosphate salt when preparing media with SDS

Table 1. Commonly Used Surfactants with Critical Micelle Concentrations Routinely, the dissolution medium is buffered, however, the use of purified water as the dissolution medium is suitable for products with a dissolution behavior independent of the pH of the medium. There are several reasons why purified water may not be preferred. The water quality can vary depending on its source, and the pH of the water is not as strictly controlled as the pH of buffer solutions. Additionally, the pH can vary from day to day and can also change during the run, depending on the active substance and excipients. Use of an aqueous–organic solvent mixture as a dissolution medium is discouraged; however, with proper justification this type of medium may be acceptable. Investigations of the stability of the drug substance should be carried out, when needed, in the selected dissolution medium with excipients present, at 37°. Sufficient time should be allowed to complete or repeat the analytical procedure. This elevated temperature has the potential to decrease solution stability (degradation). Physical stability may be of concern when precipitation occurs because of lower solubility at room or refrigerated temperature. 1.3 Choosing a Medium and Volume When developing a dissolution procedure, one goal is to have sink conditions, which are defined as having a volume of medium at least three times the volume required to form a saturated solution of drug substance. When sink conditions are present, it is more likely that dissolution results will reflect the properties of the dosage form. A medium that fails to provide sink conditions may be acceptable if it is appropriately justified. The appropriate composition and volume of dissolution medium are defined by the solubility investigations. The use of surfactants needs to be justified by data that show low solubility in the aqueous media. The chosen concentration of surfactant also needs to be justified by providing dissolution profiles in media containing the surfactant at concentrations higher and lower than the chosen concentration. The use of enzymes in the dissolution medium is permitted, in accordance with general chapter Dissolution 711 , when dissolution failures occur as a result of cross-linking with gelatin capsules or gelatin-coated products. A discussion of the phenomenon of cross-linking and method development using enzymes can be found in proposed Surfactant CMC (% wt/volume) Ref. Anionic Sodium dodecyl sulfate (SDS), Sodium lauryl sulfate (SLS) 0.18–0.23% (1–3) Taurocholic acid sodium salt 0.2% (2) Cholic acid sodium salt 0.16% (2) Desoxycholic acid sodium salt 0.12% (2) Cationic Cetyltrimethyl ammonium bromide (CTAB, Hexadecyltrimethylammonium bromide) 0.033%–0.036% (0.92–1.0 mM) (4,5) Benzethonium chloride (Hyamine 1622) 0.18% (4 mM) (1) Nonionic Polysorbate 20 (Polyoxyethylene (20) sorbitan monolaurate, Tween 20) 0.006%–0.093% (2) Polysorbate 80 (Polyoxyethylene (80) sorbitan monooleate, Tween 80) 0.002 %– 0.082% (2) Caprylocaproyl polyoxyl-8 glycerides (Labrasol) 0.01% (3) Polyoxyl 35 castor oil (Cremophor EL) 0.02% (6) Polyoxyethylene 23 lauryl ether (Brij 35) 0.013% (7) Zwitterion Lauryldimethylamine N-oxide (LDAO) 0.023% (8 


 Routinely, the dissolution medium is buffered, however, the use of purified water as the dissolution medium is suitable for products with a dissolution behavior independent of the pH of the medium. There are several reasons why purified water may not be preferred. The water quality can vary depending on its source, and the pH of the water is not as strictly controlled as the pH of buffer solutions. Additionally, the pH can vary from day to day and can also change during the run, depending on the active substance and excipients. Use of an aqueous–organic solvent mixture as a dissolution medium is discouraged; however, with proper justification this type of medium may be acceptable. Investigations of the stability of the drug substance should be carried out, when needed, in the selected dissolution medium with excipients present, at 37°. Sufficient time should be allowed to complete or repeat the analytical procedure. This elevated temperature has the potential to decrease solution stability (degradation). Physical stability may be of concern when precipitation occurs because of lower solubility at room or refrigerated temperature

1.3 Choosing a Medium and Volume When developing a dissolution procedure, one goal is to have sink conditions, which are defined as having a volume of medium at least three times the volume required to form a saturated solution of drug substance. When sink conditions are present, it is more likely that dissolution results will reflect the properties of the dosage form. A medium that fails to provide sink conditions may be acceptable if it is appropriately justified. The appropriate composition and volume of dissolution medium are defined by the solubility investigations. The use of surfactants needs to be justified by data that show low solubility in the aqueous media. The chosen concentration of surfactant also needs to be justified by providing dissolution profiles in media containing the surfactant at concentrations higher and lower than the chosen concentration. The use of enzymes in the dissolution medium is permitted, in accordance with general chapter Dissolution 711 , when dissolution failures occur as a result of cross-linking with gelatin capsules or gelatin-coated products. A discussion of the phenomenon of cross-linking and method development using enzymes can be found in proposed

general information chapter Capsules–Dissolution Testing and Related Quality Attributes 1094 . Another option is to use media that follow more closely the composition of fluids in the stomach and intestinal tract. These media may contain physiological surface-active ingredients, such as taurocholate. They may contain emulsifiers (lecithin) and components such as saline solution that increase osmolality. Also, the ionic strength or molarity of the buffer solutions may be manipulated. The media are designed to represent the fed and fasted state in the stomach and small intestine. These media may be very useful in modeling in vivo dissolution behavior of immediate-release (IR) dosage forms, in particular those containing lipophilic drug substances, and may help in understanding the dissolution kinetics of the product related to the physiological make-up of the digestive fluids. Results of successful modeling of dissolution kinetics have been published, mainly for IR products. In the case of extended-release dosage forms with reduced effect of the drug substance on dissolution behavior, the use of such media needs to be evaluated differently. In vitro performance testing does not necessarily require media modeling the fasted and postprandial states (9,10). An acid stage is part of the testing of delayed-release products by Method A or Method B in chapter 711 . For poorly acid-soluble drugs or drugs that degrade in acid there is a challenge of detecting the drug, therefore guaranteeing passing the 10% limit. This would be handled on a case-by-case basis. Possible resolutions include the addition of surfactant to the acid stage, or adjustment of the specifications. During selection of the dissolution medium, care should be taken to ensure that the sample is suitably stable throughout the analysis. In some cases, antioxidants such as ascorbic acid may be used in the dissolution medium to stabilize the drug. There are occasions where such actions are not sufficient. For compounds that rapidly degrade to form a stable degradant, monitoring the degradant alone or in combination with a drug substance may be more suitable than analyzing only the drug substance. In situ spectroscopic techniques tend to be less affected by degradation when compared with HPLC analysis. For compendial Apparatus 1 (basket) and Apparatus 2 (paddle), the volume of the dissolution medium can vary from 500 to 1000 mL, with 900 mL as the most common volume. Usually, the volume needed for the dissolution test can be determined in order to maintain sink conditions. In some cases, the volume can be increased to between 2 and 4 L, using larger vessels and depending on the concentration and sink conditions of the drug; justification for this approach is expected. In practice, the dissolution medium is usually changed to maintain the volume at 500–1000 mL. Alternatively, it may be preferable to switch to other compendial apparatus, such as a reciprocating cylinder (Apparatus 3), reciprocating holder (Apparatus 7), or flow-through cell (Apparatus 4). Certain applications may require low volumes of dissolution media (e.g., 100–200 mL) when the use of a paddle or basket is preferred. In these cases, an alternative, noncompendial apparatus (e.g., small-volume apparatus) may be used. 1.4 Choosing an Apparatus The choice of apparatus is based on knowledge of the formulation design and the practical aspects of dosage form performance in the in vitro test system. In general, a compendial apparatus should be selected. For solid oral dosage forms, Apparatus 1 and Apparatus 2 are used most frequently. When Apparatus 1 or Apparatus 2 is not appropriate, another official apparatus may be used. Apparatus 3 (reciprocating cylinder) has been found especially useful for chewable tablets, soft gelatin capsules, delayed-release dosage forms, and nondisintegrating-type products, such as coated beads. Apparatus 4 (flow-through cell) may offer advantages for modified-release dosage forms and immediate-release dosage forms that contain active ingredients with limited solubility. In addition, Apparatus 4 may have utility for soft gelatin capsules, beaded products, suppositories, or injectable-depot dosage forms, as well as suspension-type extended-release dosage forms for oral or parenteral use, or ocular application. Apparatus 5 (paddle over disk) and Apparatus 6 (rotating cylinder) are useful for evaluating and testing transdermal dosage forms. Apparatus 7 (reciprocating holder) has application to non-disintegrating, oral modified-release dosage forms, stents, and implants, as well as transdermal dosage forms. For semisolid dosage forms, the generally used apparatus include the vertical diffusion cell, immersion cell, and flow-through cell apparatus with the insert for topical dosage forms (see Semisolid Drug Products—Performance Tests 1724 ). Some changes can be made to the compendial apparatus; for example, a basket mesh size other than the typical 40-mesh basket (e.g., 10-, 20-, or 80-mesh) may be used when the need is clearly documented by supporting data. Care must be taken that baskets are uniform and meet the dimensional requirements specified in 711 . A noncompendial apparatus may have some utility with proper justification, qualification, and documentation of superiority over the standard equipment. For example, a small-volume apparatus with mini paddles and baskets may be considered for low-dosage strength products. A rotating bottle or dialysis tubes may have utility for microspheres and implants; peak vessels for eliminating coning; and modified flow-through cells for special dosage forms including powders and stents.  

Dissolution Development Chapter 1

Posted by kaushik zala

About Me

My photo
gandhinagar, gujarat, India
HPLC LOVER

Labels

MY PHOTOS ON FACE BOOK

MY OLDER BLOGS

MY FACE BOOK PROFILE

KAUSHIK ZALA, HPLC SCIENTIST. Powered by Blogger.
Copyright © 2013 Yours Chromatographically, Kaushik Zala | Dark Simple Blogger Template Powered by Blogger | Created by Renadel Dapize | Ori. BRS-bt Djogzs | All Rights Reserved